Treatment of PPD with SSRIs: Long-Term Benefits for Both Mother and Child
Postpartum SSRI treatment mitigated the negative associations between PPD and later maternal depression, partner relationship satisfaction, and child externalizing problems and ADHD symptoms up to 5 years after childbirth.
Largest-Ever Genetic Study of PPD: Correlations Between PPD and Other Psychiatric Disorders, Evidence of Involvement of GABAergic Systems
The largest GWAS study to date provides evidence that despite a high correlation with MDD, PPD may have unique genetic components.
Clinical Update 2024: Recommendations on the Use of Antidepressants in Women Taking Tamoxifen
While some antidepressants may affect the metabolism and efficacy of tamoxifen, many antidepressants can be used safely in this population.
Antipsychotic Medications: Women and Men Respond Differently
Understanding important differences between men and women in terms of response to antipsychotic medications is essential to improving outcomes and decreasing risk for side effects.
Weekly Roundup for February 9, 2024: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
What is Dexmedetomidine? And Does it Prevent Postpartum Depression?
Dexmedetomidine, an α2-adrenergic receptor agonist, shows promise in preventing postpartum depression, reducing symptoms and improving sleep and pain control in women with prenatal depression.
Is Postpartum Depression More Common in Women with Sensitivity to Hormonal Contraceptive?
A history of hormonal contraception-associated depression may be associated with a higher risk for postpartum depression.
Danish Study Indicates No Increase in Risk of Malformations with Prenatal Exposure to Antipsychotic Medications
This register-based cohort study from Denmark of 503,158 clinically recognized pregnancies observed little or no risk of teratogenesis associated with first trimester exposure to antipsychotic medications.